You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The EPO rejected arguments that were filed in opposition to the patent, which covers the use of CRISPR-Cas9 in cellular and non-cellular settings.
The company said revenue growth during the year was driven by performance in its research reagents and screening business units.
The company, which recently signed a licensing agreement with Horizon Discovery, just raised $45 million in a Series B financing round.
The European Patent Office appeals board upheld the decision made by the EPO after its initial review in 2018.
Jennifer Doudna and Emmanuelle Charpentier are being awarded Israel's Wolf Prize in medicine for their CRISPR work, the Associated Press reports.
In PNAS this week: population genomics study on indigenous individuals in Brazil, programmable genome-editing approach, and more.
Horizon also said it will provide access to the technology to business partners for the development of more effective multi-gene knockout cell therapy programs.
Daiichi Sankyo plans to use the ERS IP to support its own R&D initiatives to address areas of unmet medical need, the company said.
Dalhousie University's Françoise Baylis discusses He Jiankui and the ethics of heritable human genome editing research in a Boston Globe op-ed.
NEB plans to expand its product lines into new areas of research including genome editing, the companies said.
NPR reports that researchers have developed chimeric embryos as part of work toward growing human organs in animals for organ transplants.
According to the Washington Post, the Biden Administration is set to make changes to federal restrictions on fetal tissue research.
In Science this week: approach to isolated trace DNA from archaic humans from sediments, and more.
Texas Monthly looks into the DNA Zoo being collected by Baylor College of Medicine researchers.